Methods and compositions for sequencing modified nucleic acids

• US 9,238,836 B2
• Filed: 03/15/2013
• Issued: 01/19/2016
• Est. Priority Date: 03/30/2012
• Status: Active Grant

• Current Assignee: Pacific Bioscience of California Incorporated (L'Oreal SA)
• Original Assignee: Pacific Bioscience of California Incorporated (L'Oreal SA)
• Inventors: Korlach, Jonas, Turner, Stephen, Clark, Tyson A.
• Primary Examiner(s): Mummert, Stephanie K
• Assistant Examiner(s): PRIEST, AARON A
• Application Number:
  US13/836,806
• Publication Number:
  US 20130303385A1
• Time in Patent Office: 1,040 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/6874 involving nucleic acid arrays, e.g. sequencing by hybridisation
• CPC Class Codes: C12Q 2521/514 Mismatch repair protein
• CPC Class Codes: C12Q 2523/125 Bisulfite(s)
• CPC Class Codes: C12Q 2535/122 Massive parallel sequencing
• CPC Class Codes: C12Q 2565/518 characterised by the immobilisation of the nucleic acid sample or target

Abstract

Methods, compositions, and systems are provided for characterization of modified nucleic acids. In certain preferred embodiments, single molecule sequencing methods are provided for identification of modified nucleotides within nucleic acid sequences. Modifications detectable by the methods provided herein include chemically modified bases, enzymatically modified bases, abasic sites, non-natural bases, secondary structures, and agents bound to a template nucleic acid.

Claims

1. A method for identifying sequence differences between two nucleic acids from different sources, the method comprising:

a) providing a first nucleic acid from a first sample;

b) providing a second nucleic acid from a second sample;

c) treating the first nucleic acid to produce a modified nucleic acid;

d) denaturing the modified nucleic acid and the second nucleic acid;

e) annealing the modified nucleic acid to the second nucleic acid, thereby producing hybrid nucleic acids that comprise a modified strand from the first sample and an unmodified strand from the second sample, and further wherein a subset of the hybrid nucleic acids comprise non-complementary regions of one or more base pairs due to sequence differences between the modified strand and the unmodified strand;

f) binding a non-complementary-region-specific binding agent selected from the group consisting of a single-strand-specific binding agent and a mismatch-repair agent to the subset of the hybrid nucleic acids, wherein the non-complementary-region-specific binding agent comprises a selectable tag;

g) capturing the subset of the hybrid nucleic acids bound to the non-complementary-region-specific binding agent using the selectable tag;

h) removing nucleic acids not bound to the non-complementary-region-specific binding agent;

i) subjecting the subset of the hybrid nucleic acids to a single type of sequencing reaction in which both the first and second strands of the hybrid nucleic acids are sequenced and both sequence data and modification data are provided in a single sequence read;

j) for each sequence read, analyzing the sequencing data to identify said non-complementary regions; and

k) for each sequence read, analyzing the modification data to determine which subset of said sequence read corresponds to the modified strand and which subset corresponds to the unmodified strand, thereby identifying sequence differences between the first nucleic acid from the first sample and the second nucleic acid from the second sample.

2. The method of claim 1, wherein the treating introduces one or more modifications into the first nucleic acid that render it distinguishable from the second nucleic acid.

3. The method of claim 2, wherein the modifications comprise one or more of methylation, demethylation, hydroxymethylation, or glucosylation.

4. The method of claim 1, wherein the first sample is a tumor sample and the second sample is a non-tumor sample, and further wherein the sequence differences identified correspond to mutations that occurred during development of a tumor.

5. The method of claim 1, wherein the non-complementary-region-specific agent is selected from a single-strand-specific binding agent and a mismatch-repair agent.

6. The method of claim 1, wherein subsequent to the annealing and prior to the subjecting, incorporating the hybrid nucleic acids into template molecules having at least one adapter that links the modified strand to the unmodified strand.

7. The method of claim 6, wherein the incorporating occurs prior to the capturing.

8. A method for identifying loci where two nucleic acids from two different sources are non-complementary, the method comprising:

a) providing a first nucleic acid from a first sample;

b) providing a second nucleic acid from a second sample;

c) denaturing the first nucleic acid and the second nucleic acid;

d) annealing the first nucleic acid to the second nucleic acid, thereby producing hybrid nucleic acids that comprise a first strand from the first sample and a second strand from the second sample, and further wherein a subset of the hybrid nucleic acids comprise non-complementary regions of one or more base pairs due to sequence differences between the first strand and the second strand;

e) performing mismatch repair on the hybrid nucleic acids using modified nucleotides comprising a selectable tag, thereby generating repaired hybrid nucleic acids;

f) isolating the repaired hybrid nucleic acids using the selectable tag;

g) subjecting the repaired hybrid nucleic acids to a single type of sequencing reaction in which both the first and second strands of the repaired hybrid nucleic acids are sequenced and both sequence data and modification data are provided in a single sequence read; and

h) for each sequence read, analyzing the sequence data and modification data to determine which subset of said sequence read comprises the modified nucleotides, thereby identifying loci at which the first nucleic acid and second nucleic acid were non-complementary.

9. The method of claim 8, wherein the modified nucleotides comprise one or more of methylated nucleotides, hydroxymethylated nucleotides, or glucosylated nucleotides.

10. The method of claim 8, wherein the first sample is a tumor sample and the second sample is a non-tumor sample, and further wherein the loci at which the first nucleic acid and second nucleic acid were non-complementary correspond to mutations that occurred during development of a tumor.

11. The method of claim 8, wherein subsequent to the annealing and prior to the subjecting, incorporating the hybrid nucleic acids into template molecules having at least one adapter that links the first strand to the second strand.

12. The method of claim 11, wherein the incorporating occurs prior to the capturing.